Search

PPI-1019

Apan (PPI-1019) is developed by Praecis Pharmaceuticals to treat Alzheimer's Disease.

UB-612

The vaccine incorporates a strong S1-RBD component linked to a single chain fragment region (sFC) of a human IgG1, which facilitates cell attachment and acts as the principal neutralizing domain of the … This vaccine was designed to induce a broad immune response. It was able to reduce viral load and prevent COVID-19 infection in a mouse challenge model and in rhesus macaques[L30653, L30658].

NTx-265

NTx-265 is a combination of two currently marketed large molecules designed to stimulate the growth and differentiation of neural stem cells in adults who have suffered a stroke – the second leading cause … In May 2006, biotechnology company Stem Cell Therapeutics started a Phase IIa study of NTx-265.

KBP-COVID-19

As of July 2020, KBP is conducting a Phase 1/2 clinical trial to evaluate the safety and immunogenicity of KBP-COVID-19 vaccine in healthy patients (NCT04473690). … KBP cloned COVID-19’s genetic sequence, identified a potential antigen, and then inserted it into tobacco plants for reproduction.

1D09C3

1D09C3, a monoclonal antibody against lymphoid cancers, is an anti-MHC (major histocompatibility complex) class II monoclonal antibody. … selectively killing activated, proliferating MHC class II-positive tumor cells, which include those in B-cell and T-cell lymphomas. 1D09C3 has been shown to induce programmed cell death and does not require a

Mesterolone

Experiments of mesterolone serving as a potential treatment of depression are still undergoing. … It is inactivated by 3α-hydroxysteroid dehydrogenase in skeleta muscules so it is considered a weak androgen. It is not a substrate for aromatase so it is not converted into estrogen.

Muraglitazar

In addition to improvements in blood glucose and hemoglobin A1c (HbA1c), muraglitazar treatment is associated with a substantial reduction in triglycerides (TGs), an increase in HDL-C, and a modest decrease … Muraglitazar (Bristol-Myers Squibb/Merck) is a new agent under investigation for the treatment of patients with type 2 diabetes.

Cyclic GMP

It is a cellular regulatory agent and has been described as a second messenger. … Cyclic guanosine monophosphate (Cyclic GMP) is a guanine nucleotide containing one phosphate group which is esterified to the sugar moiety in both the 3'- and 5'-positions.

Abafungin

Polaprezinc

Polaprezinc is a chelated form of zinc and L-carnosine. It is a zinc-related medicine approved for the first time in Japan, which has been clinically used to treat gastric ulcers [L1307, L1308]. … A study in 2013 showed that CO-administration of polaprezinc may be effective against small intestine mucosal injury associated with long-term aspirin therapy [A7840].